



ICONIC

Julphar

REDEFINING MEDICINE

The future of Pharmaceuticals in gulf is on the high road and one of the major players driving the industry is Julphar Gulf Pharmaceutical Industries. It is the largest generic pharmaceutical manufacturer in Middle East and North Africa and distributes medicines to over 40 countries.

1980 witnessed His Highness Sheikh Saqr Bin Mohammed Al Qasimi laying the foundation stone of Julphar in the the United Arab Emirates and initially

the brand's first stand-alone facility produced only five products. It took the brand nearly three decades to operate from sixteen internationally certified manufacturing facilities globally and produce over a million boxes of medicines daily and hold 4,074 product registration certificates.

Julphar has thirteen of its facilities with base in the UAE which also cover production areas including tablets, syrups and suspensions. The brand has also launched manufacturing facilities in Ethiopia, Bangladesh and Saudi Arabia as part of its ongoing international expansion strategy.

The year 2012 saw the brand inducting a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility called Julphar Diabetes which is – entirely in dedicated to producing raw material needed for insulin formulation. Julphar Diabetes has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA), equivalent to 40 million vials of insulin per year. This positions Julphar among the largest manufacturers of insulin in




the world, and the only one of its kind in the Middle East.

ILLUMINATING THE SUCCESS ROAD

The brand adorns a diverse product portfolio which targets major therapeutic segments including categories like Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care.

Julphar closely understands the need of the sector in the Gulf region and as a part of its on-going responsibility it partners with local and global companies to make a positive impact across all healthcare sectors by funding scholarships for educational facilities and by providing sponsorship of various health campaigns





across MENA.

Julphar recorded registered sales revenue of AED 1.45 billion in the year ending 2016 which is a significant number based on last year's result and all this was accomplished with the help of a team of 3,000 dedicated people. Emerging markets remain a key priority for sustainable growth, as Julphar's Middle Eastern roots allow us to reach difficult markets in a timely manner.

STRONG PLAYER

Julphar is a stellar example of one of the UAE's local businesses making an impact on the global stage with

83 registered products sold in over 40 countries. The brand is Current Good Manufacturing Practice (cGMP) compliant and has gained ISO9001 and ISO 14001 accreditations, as well as the EU Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications. We work closely with regulatory bodies, such as the UAE Ministry of Health (MOH) and the US Food and Drug Administration (FDA) to ensure all our practices are aligned with the international requirements.

The brand works with a mission to improve the patients' quality of life by providing affordable, high quality medicine through the delivery of utmost innovative and technologically advanced products. It also strives to reach exceptional growth and sustainability by operating with absolute excellence in the day to day work, and through the leaders' commitment to operate with openness and transparency in the business with the stakeholders.



QUANTUM LEAPS

- Nominee for the Company of the Year at the Gulf Business Industry Awards
- Nominee for the Mohammed Bin Rashid Al Maktoum Business Awards Ceremony